Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction

American Journal of Preventive Medicine

Volumn 55, Issue 2, 2018, Pages 197-204

  Guo, Fangjian ^a   Cofie, Leslie E ^a   Berenson, Abbey B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CAUCASIAN; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE SURVEILLANCE; FEMALE; HEALTH CARE MANAGEMENT; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PREVALENCE; SQUAMOUS CELL CARCINOMA; TREND STUDY; UNITED STATES; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VACCINATION COVERAGE; YOUNG ADULT; INCIDENCE; UTERINE CERVIX TUMOR; VACCINATION;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEER PROGRAM; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 85047640343     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2018.03.013     Document Type: Article

References (41)

1. de Sanjose, S., Quint, W.G., Alemany, L., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:11 (2010), 1048–1056, 10.1016/S1470-2045(10)70230-8.
2. Harper, D.M., Franco, E.L., Wheeler, C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:9447 (2004), 1757–1765, 10.1016/S0140-6736(04)17398-4.
3. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:19 (2007), 1915–1927, 10.1056/NEJMoa061741.
4. Joura, E.A., Giuliano, A.R., Iversen, O.E., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372:8 (2015), 711–723, 10.1056/NEJMoa1405044.
5. Petrosky, E., Bocchini, J.A. Jr., Hariri, S., et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 64:11 (2015), 300–304.
6. Reagan-Steiner, S., Yankey, D., Jeyarajah, J., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years–United States, 2015. MMWR Morb Mortal Wkly Rep 65:33 (2016), 850–858, 10.15585/mmwr.mm6533a4.
7. Hariri, S., Johnson, M.L., Bennett, N.M., et al. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer 121:16 (2015), 2775–2781, 10.1002/cncr.29266.
8. Markowitz, L.E., Hariri, S., Lin, C., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 208:3 (2013), 385–393, 10.1093/infdis/jit192.
9. Brotherton, J.M., Fridman, M., May, C.L., Chappell, G., Saville, A.M., Gertig, D.M., Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377:9783 (2011), 2085–2092, 10.1016/S0140-6736(11)60551-5.
10. Flagg, E.W., Torrone, E.A., Weinstock, H., Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007–2014. Am J Public Health 106:12 (2016), 2211–2218, 10.2105/AJPH.2016.303472.
11. Berenson, A.B., Laz, T.H., Rahman, M., Reduction in vaccine-type human papillomavirus prevalence among women in the United States, 2009–2012. J Infect Dis 214:12 (2016), 1961–1964, 10.1093/infdis/jiw515.
12. U.S. Preventive Services Task Force. The Guide to Clinical Preventive Services, 2014 www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-providers/guidelines-recommendations/guide/cpsguide.pdf Accessed March 8, 2018.
13. Saslow, D., Solomon, D., Lawson, H.W., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62:3 (2012), 147–172, 10.3322/caac.21139.
14. Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol 120:5 (2012), 1222–1238.
15. NPCR and SEER Incidence–USCS Public Use Databases. www.cdc.gov/cancer/npcr/public-use/index.htm. Accessed October 15, 2017.
16. Nitschmann, C., May, T., Mirkovic, J., Feldman, S., Screening history among women with invasive cervical cancer in an academic medical center: will we miss cancers following updated guidelines?. J Womens Health (Larchmt) 25:8 (2016), 826–831, 10.1089/jwh.2015.5394.
17. NAACCR Race and Ethnicity Work Group. NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2.2.1]. September, 2011, North American Association of Central Cancer Registries, Springfield, IL.
18. Tiwari, R.C., Clegg, L.X., Zou, Z., Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res 15:6 (2006), 547–569, 10.1177/0962280206070621.
19. Kim, H.J., Fay, M.P., Feuer, E.J., Midthune, D.N., Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:3 (2000), 335–351 http://doi.org/10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336<3.0.CO;2-Z.
20. Joinpoint Regression Program, Version 4.5.0.1 - June 2017; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute.
21. Public-Use Data Files and Documentation. www.cdc.gov/nchs/data_access/ftp_data.htm. Accessed January 12, 2018.
22. Meites, E., Kempe, A., Markowitz, L.E., Use of a 2-dose schedule for human papillomavirus vaccination–updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 65:49 (2016), 1405–1408, 10.15585/mmwr.mm6549a5.
23. Drolet, M., Bénard, É., Boily, M.C., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15:5 (2015), 565–580, 10.1016/S1473-3099(14)71073-4.
24. Markowitz, L.E., Liu, G., Hariri, S., Steinau, M., Dunne, E.F., Unger, E.R., Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 137:3 (2016), 1–9, 10.1542/peds.2015-1968.
25. Guo, F., Hirth, J.M., Berenson, A.B., Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20–26 years). Hum Vaccin Immunother 11:10 (2015), 2337–2344, 10.1080/21645515.2015.1066948.
26. Oliver, S.E., Unger, E.R., Lewis, R., et al. Prevalence of human papillomavirus among females after vaccine introduction-National Health and Nutrition Examination Survey, United States, 2003–2014. J Infect Dis 216:5 (2017), 594–603, 10.1093/infdis/jix244.
27. Hirth, J.M., Chang, M., Resto, V.A., Group, H.S., Prevalence of oral human papillomavirus by vaccination status among young adults (18–30 years old). Vaccine 35:27 (2017), 3446–3451, 10.1016/j.vaccine.2017.05.025.
28. Berenson, A.B., Hirth, J.M., Chang, M., Change in human papillomavirus prevalence among U.S. women aged 18-59 years, 2009–2014. Obstet Gynecol 130:4 (2017), 693–701, 10.1097/AOG.0000000000002193.
29. Hariri, S., Bennett, N.M., Niccolai, L.M., et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States–2008–2012. Vaccine 33:13 (2015), 1608–1613, 10.1016/j.vaccine.2015.01.084.
30. Mahmud, S.M., Kliewer, E.V., Lambert, P., Bozat-Emre, S., Demers, A.A., Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol 32:5 (2014), 438–443, 10.1200/JCO.2013.52.4645.
31. Pollock, K.G., Kavanagh, K., Potts, A., et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 111:9 (2014), 1824–1830, 10.1038/bjc.2014.479.
32. Baldur-Felskov, B., Dehlendorff, C., Junge, J., Munk, C., Kjaer, S.K., Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 25:7 (2014), 915–922, 10.1007/s10552-014-0392-4.
33. Benard, V.B., Thomas, C.C., King, J., Massetti, G.M., Doria-Rose, V.P., Saraiya, M., Vital signs: cervical cancer incidence, mortality, and screening–United States, 2007–2012. MMWR Morb Mortal Wkly Rep 63:44 (2014), 1004–1009.
34. Beachler, D.C., Tota, J.E., Silver, M.I., et al. Trends in cervical cancer incidence in younger U.S. women from 2000 to 2013. Gynecol Oncol 144:2 (2017), 391–395, 10.1016/j.ygyno.2016.11.031.
35. CDC. Sexually Transmitted Disease Surveillance 2016. 2017, HHS, Atlanta, GA.
36. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin no. 109: cervical cytology screening. Obstet Gynecol 114:6 (2009), 1409–1420, 10.1097/AOG.0b013e3181c6f8a4.
37. Whitlock, E.P., Vesco, K.K., Eder, M., Lin, J.S., Senger, C.A., Burda, B.U., Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 155:10 (2011), 687–697, 10.7326/0003-4819-155-10-201111150-00376.
38. Saslow, D., Runowicz, C.D., Solomon, D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52:6 (2002), 342–362, 10.3322/canjclin.52.6.342.
39. Castanon, A., Landy, R., Sasieni, P.D., Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?. Int J Cancer 139:5 (2016), 1040–1045, 10.1002/ijc.30152.
40. Wang, S.S., Sherman, M.E., Hildesheim, A., Lacey, J.V., Devesa, S., Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 100:5 (2004), 1035–1044, 10.1002/cncr.20064.
41. Castellsagué X., Díaz, M., de Sanjosé S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:5 (2006), 303–315, 10.1093/jnci/djj067.